Import Alert 54-18 lets FDA detain supplements and bulk dietary ingredients from listed firms without examining them when they are or contain a new dietary ingredient (NDI) that FDA finds lacks adequate safety information. An NDI is one not marketed in the U.S. before October 15, 1994. Higenamine from Chinese suppliers is the main listing today.
Listed on 54-18? Send us the firm name, ingredient and FDA notice. We review the NDI status and prepare the release or removal evidence.
Get a 54-18 Case Review| Item | Import Alert 54-18 |
|---|---|
| Official title | DWPE of Dietary Supplements and Bulk Dietary Ingredients That Are or Contain New Dietary Ingredients |
| NDI | A dietary ingredient not marketed in the U.S. before October 15, 1994 (section 413(d)) |
| Charge | Section 402(f)(1)(B), refusal under 801(a)(3); code NDIDIETSP |
| Listed ingredients | Higenamine and Sakae NAA |
| Countries | China |
| Removal contact | Importalerts2@fda.hhs.gov |
Details follow the current text of Import Alert 54-18, published June 27, 2025.
Bulk higenamine sold as a botanical or dietary specialty ingredient.
A listed dietary specialty ingredient.
Powders and raw materials sold to supplement makers.
Supplements labeled as containing a listed NDI.
Botanical ingredients not in teas, NEC.
Vitamins, proteins and unconventional dietary specialties, NEC.
To release a detained shipment, the owner, consignee or other responsible party shows the product is not or does not contain a new dietary ingredient, or provides all relevant information demonstrating the NDI's safety, such as an NDI notification. Send it to the FDA Division compliance office in the notice.
Information showing the firm has resolved the conditions behind the listing, for example that it no longer supplies the NDI for U.S. supplement use or has safety information FDA accepts, emailed to Importalerts2@fda.hhs.gov under RPM Chapter 9-8.
FDA's framework is in RPM Chapter 9-8; FDA removal guidance explains what a request should include.
Removal help for food and supplements.
Kratom supplements.
Supplements with hidden drugs.
Supplements not meeting GMP.
Supplement registration and labeling.
Check claims and ingredient labeling.
We review the ingredient's NDI status, advise on the realistic route and prepare the release or removal evidence. We are an independent compliance firm, not FDA or a law firm, and no one can guarantee FDA's decision.
Contact our specialists, email info@fdaregistrationassistance.com, or call +1 (928) 275-8333. Import alert removal · Supplement services · Contact.
Get a 54-18 Case ReviewFDA Registration Assistance is a private consulting firm, not FDA or any government agency. FDA registration is not FDA approval, clearance or certification.
Import Alert 54-18 is titled "Detention Without Physical Examination of Dietary Supplements and Bulk Dietary Ingredients That Are or Contain New Dietary Ingredients." It lets FDA detain listed products without examining each shipment.
A dietary ingredient that was not marketed in the United States before October 15, 1994, as defined in section 413(d) of the FD&C Act.
FDA reviewed the products on the Red List and found they are or contain one or more NDIs with inadequate information to provide reasonable assurance they do not present a significant or unreasonable risk of illness or injury. That makes them adulterated.
Refusal under section 801(a)(3) because the article appears to be a dietary supplement or contain an NDI without adequate safety information, adulteration under section 402(f)(1)(B). The OASIS code is NDIDIETSP.
Higenamine, listed for two Chinese firms, and Sakae NAA, listed for one. All current listings are in China.
Yes. The alert says FDA's Human Foods Program can evaluate evidence case by case to add a listed NDI, alone or as an ingredient, offered for import by a firm not already listed.
Open Import Alert 54-18 and search the Red List by country and firm name. Each entry shows the product and the date it was added. Check before every shipment season, since the alert is updated often.
Give the FDA Division compliance office evidence that the product is not or does not contain a new dietary ingredient, or all relevant information demonstrating the NDI's safety, such as an NDI notification.
A premarket notice to FDA, at least 75 days before marketing, giving the basis for concluding a supplement with the NDI will reasonably be expected to be safe. It is required unless the ingredient was present in the food supply as an article used for food in a form not chemically altered.
Yes, if you have reliable evidence it was marketed as a dietary ingredient in the U.S. before October 15, 1994, such as dated catalogs, invoices or labels. That evidence must match the same ingredient in the same form.
Show FDA that the firm has resolved the conditions behind the listing, so it is confident future entries will comply. Email Importalerts2@fda.hhs.gov, following RPM Chapter 9-8.
Both use the same NDI charge. Import Alert 54-15 is only for kratom, while 54-18 covers other NDIs FDA has found unsafe, currently higenamine and Sakae NAA.
Removal petitions go to Importalerts2@fda.hhs.gov. The alert lists the Division of Import Operations at (301) 796-0356 or Imports@fda.hhs.gov, and HFP-OCE-Imports@fda.hhs.gov for policy questions.
We can review the ingredient's status and help organize the records and safety information for a notification. The safety evidence itself must come from qualified experts. See our dietary supplement services.
No. FDA makes every removal decision. We are an independent compliance firm, not FDA or a law firm. We help you build a complete, well-documented request.
Tell us what your company makes, sells, or distributes, where each product is manufactured or packed, your U.S. importer or buyer arrangement, label readiness, and target shipment date.
Submitting this inquiry does not purchase a service or authorize paid work. Our team can discuss the scope and required materials before you commission assistance. Fields marked with an asterisk are required.